European Medical Solutions

Major Shareholding Notification • Jan 7, 2019

Regulated information

Publication related to a transparency notification

(article 14, subparagraph 1 of the law of 2 May 2007 regarding the disclosure of important shareholdings in listed companies)

Brussels, Belgium, 7 January 2019, 5.45 pm (CET) – ASIT biotech (ASIT - BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, today announces that it has received a transparency notification dated 4 January, 2019, the result of which is - as a result of which people don't act anymore in concert and the threshold of participation of 5% isn't crossed anymore.

The statement dated 4 January 2019 notably includes the following information:

• Purpose of the notification

End of a concerted action agreement

• Notification by

People acting in concert

• Person subject to the notification requirement

Chagral Invest SPRL : 523, Avenue Louise – 1050 Bruxelles 3T Finance SA : 6B bt7, Avenue Lloyd George – 1000 Bruxelles

• Date of the transaction

December 27 th , 2018

• Threshold crossed (%)

The threshold of 5% is crossed

• Denominator

A total of 18,396,848 voting rights

• Details of the notification

A) Voting rights	Previous notification	After the transaction
	# voting rights	# voting rights		% of voting rights
Holders of voting rights		Attached to shares	Non attached to shares	Attached to shares	Non attached to shares
CHAGRAL INVEST SPRL		406,913		2.21%
3T FINANCE SA		671,074		3.65%
Sub-total
	TOTAL

• Chain of controlled companies through which the participation is actually held

CHAGRAL INVEST and 3T FINANCE SA are not controlled within the meaning of Articles 5 and 7 of the Company Code

• This notification is available on ASIT biotech's website, in the Documentation / Regulated information section:

https://www.asitbiotech.com/investors/documentation

***

About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech's product pipeline contains three novel ASIT+™ product candidates targeting respiratory allergies with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), and food allergies (peanut allergy: pnt-ASIT+™) that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

ASIT biotech has a headcount of 26 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.

Further information can be found at www.asitbiotech.com.

Contacts

Company Michel Baijot, Managing Director ASIT biotech Tel.: +32 2 264 03 90 investors@asitbiotech.com

Media and Investor Relations - France NewCap Dusan Oresansky / Pierre Laurent Tel.: +33 1 44 71 94 92 asitbiotech@newcap.eu

Media Relations - Belgium Laure-Eve Monfort Tel.: +32 2 290 90 93 monfort@comfi.be